Phase-1 Clinical Trial Results of High-Specific-Activity Carrier-Free <sup>123</sup>I-Iobenguane

201421 citationsJournal Articlebronze Open Access

Authors

Bennett B. Chin · Duke Medical Center

James F. Kronauge · Insight Therapeutics

F.J. Femia · Insight Therapeutics

Jianqing Chen · Insight Therapeutics

Kevin Maresca · Insight Therapeutics

Shawn Hillier · Insight Therapeutics

Neil A. Petry ·

Abstract

Human normal-organ kinetics, radiation dosimetry, clinical safety, and imaging efficacy provide compelling evidence for the use of high-specific-activity (123)I-iobenguane.

Topics & Keywords

Medical Imaging Techniques and Applications Radiopharmaceutical Chemistry and Applications Advanced MRI Techniques and Applications

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Nuclear Medicine

Volume 55, Issue 5, pp. 765-771

DOI: 10.2967/jnumed.113.124057

Field-Weighted Citation Impact: 0.52